Actively Recruiting
Intra-lesional Tumor Boost for Bulky Cervical Cancer
Led by Seoul National University Bundang Hospital · Updated on 2026-02-27
17
Participants Needed
1
Research Sites
196 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if adding a radiation boost (intra-lesional boost) works to treat patients with large-sized cervical cancer. It will also learn about the safety of this treatment. The main questions it aims to answer are: * Does the extra radiation boost effectively reduce the tumor size before the internal radiation (brachytherapy) treatment begins? * What medical problems (side effects) do participants have when receiving this treatment? Researchers will give this intra-lesional boost to all participants during their standard radiation therapy to see if it helps shrink the tumor more than usual. Participants will: * Receive radiation therapy to the pelvis with a targeted boost to the tumor for about 5 to 6 weeks * Visit the clinic daily for radiation treatment and regularly for checkups Have an MRI scan during the 4th or 5th week of treatment to measure the tumor size * Receive internal radiation therapy (brachytherapy) after finishing the external radiation * Visit the clinic for follow-up checkups and tests for up to 2 years
CONDITIONS
Official Title
Intra-lesional Tumor Boost for Bulky Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with histologically confirmed squamous cell carcinoma of the cervix.
- Patients with bulky primary tumor, defined as a tumor volume 362 60 cc OR a maximum diameter 336 cm.
- Patients aged 19 to 80 years at the time of diagnosis.
- Patients with an ECOG performance status of 0 to 2.
- Patients who have voluntarily agreed to participate in the study.
You will not qualify if you...
- Diagnosis of other malignancies within 5 years prior to enrollment (Exceptions: carcinoma in situ of the breast and thyroid cancer).
- Patients who are medically unfit for definitive concurrent chemoradiotherapy.
- Patients who have received prior chemotherapy (neoadjuvant chemotherapy) before radiation therapy.
- Patients with prior history of radiation therapy to the abdomen or pelvis.
- Patients unable to provide informed consent due to mental or physical disabilities.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 13620
Actively Recruiting
Research Team
K
Keun-Yong Eom, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here